Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>>NEW! Download now...

GlaxoSmithKline to Buy Out China Vaccine JV Partner

publication date: Jun 14, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
GlaxoSmithKline is planning to take one of its China vaccine JVs entirely in-house. The company will pay $39 million to Shenzhen Neptunus Interlong Bio-Technique Co. for the 51% of their JV that it does not already own. The JV was established with the goal of supplying seasonal flu, pre-pandemic and pandemic flu vaccines for China, Hong Kong and Macau. More details....

Stock Symbols: (NYSE: GSK) (HKEX: 8329)

Share this with colleagues:  

This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events


BioPacific Conference 2012
June 2, 2012
California, USA

  China Forum 2012
  November 11, 2012
Hamburg, Germany

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners